Valuation: Xencor, Inc.

Market Cap 1.84B 1.6B 1.51B 1.37B 2.57B 176B 2.59B 18.13B 7B 89.67B 6.9B 6.75B 289B P/E 2026 *
-8.04x
P/E 2027 * -7.65x
Enterprise Value 1.41B 1.23B 1.16B 1.05B 1.97B 135B 1.98B 13.86B 5.35B 68.54B 5.28B 5.16B 221B EV / Sales 2026 *
9.81x
EV / Sales 2027 * 14.7x
Free-Float
98.78%
Yield 2026 *
-
Yield 2027 * -
1 day+1.60%
1 week+1.27%
Current month-9.33%
1 month-8.44%
3 months+95.57%
6 months+103.79%
Current year+61.46%
1 week 23.36
Extreme 23.36
25.02
1 month 23.36
Extreme 23.36
30.61
Current year 10.38
Extreme 10.375
30.61
1 year 10.04
Extreme 10.045
30.61
3 years 6.92
Extreme 6.92
30.61
5 years 6.92
Extreme 6.92
43.61
10 years 6.92
Extreme 6.92
58.34
Manager TitleAgeSince
Chief Executive Officer 55 31/01/2005
Director of Finance/CFO 48 08/04/2024
Chief Tech/Sci/R&D Officer 61 30/09/2006
Director TitleAgeSince
Director/Board Member 55 31/07/1997
Director/Board Member 58 24/07/2014
Director/Board Member 72 17/03/2015
Date Insider Type Main position Quantity % Market Cap. Importance
16/06/26 Free

Director

30,906 0.0417%
10/04/26 Sell

Chief Financial Officer

3,499 0.0048%
05/03/26 Sell

Chief Technology Officer

6,620 0.0090%
Change 5-day change 1-year change 3-year change Capi.($)
+1.60%+1.27%+140.23%+20.29% 1.84B
-0.31%+5.79%+47.13%+99.53% 70.88B
-1.03%-0.55%+36.72%+82.22% 62.49B
+5.26%+7.86%+32.24%+30.06% 26.34B
+1.60%-7.27%-17.10%+370.22% 26.21B
+1.50%-0.69%-0.17%-11.56% 24.13B
-0.13%+6.71%+24.37%-11.52% 20.72B
+2.12%-5.86%+161.58%+333.73% 15.69B
+0.07%+3.99%+45.54%+171.32% 14.46B
+0.70%+1.71%-5.51%+859.68% 14.24B
Average +1.15%+1.70%+46.50%+194.40% 27.7B
Weighted average by Cap. +0.66%+1.48%+35.78%+152.21%

Financials

2026 *2027 *
Net sales 143M 125M 118M 107M 201M 13.74B 201M 1.41B 545M 6.99B 538M 526M 22.48B 125M 109M 103M 93.25M 175M 11.97B 175M 1.23B 475M 6.08B 469M 458M 19.58B
Net income -240M -209M -197M -179M -336M -23.01B -337M -2.36B -912M -11.7B -901M -881M -37.63B -284M -248M -234M -213M -399M -27.3B -400M -2.81B -1.08B -13.88B -1.07B -1.04B -44.66B
Net Debt -433M -378M -357M -324M -607M -41.55B -609M -4.27B -1.65B -21.12B -1.63B -1.59B -67.97B -
Logo Xencor, Inc.
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Employees
260
Date Price Change Volume
18/09/26 US$24.72 +0.53% 5,207,447
17/09/26 US$24.59 +3.71% 1,027,007
16/09/26 US$23.71 -0.17% 1,230,466
15/09/26 US$23.75 -3.18% 1,818,841
14/09/26 US$24.53 +0.49% 858,322
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
24.72USD
Average target price
30.75USD
Spread / Average Target
+24.39%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. XNCR Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!